Navigation Links
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Date:11/9/2007

Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing 31% Partial Response Rate and a 62% Overall Clinical Benefit Rate to Perifosine Used as a Single Agent and Phase 1 Data Showing No Evidence of Increased

Toxicity When Combined with Sorafenib

NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced positive phase 1 & 2 data of perifosine (KRX-0401) in patients with advanced renal cell carcinoma (RCC). In an oral presentation entitled "PERIFOSINE: AN ORAL, AKT INHIBITOR WITH CLINICAL ACTIVITY IN ADVANCED RENAL CELL CARCINOMA," Dr. Robert Figlin, Medical Oncology Chair and Professor of Medicine, City of Hope National Medical Center in Duarte, CA provided an update on the clinical activity of single agent perifosine from a phase 2 trial (Protocol 207), and reported on the safety and efficacy of perifosine in combination with sorafenib from an ongoing phase I study (Protocol 124).

Phase 2 Single Agent in RCC - Protocol 207

Twenty-four patients with advanced renal cell carcinoma (RCC) were randomized to either the daily (50 mg or 100mg) or weekly (900mg or 1200mg) dose of perifosine. Patients with measurable disease who received at least 2 courses of perifosine and at least one tumor measurement after initiation of perifosine, were considered evaluable for response using RECIST criteria. Thirteen were evaluable for response. Four of these (31%) had a partial response and an additional 4 patients (31%) achieved long-term stable disease for a 62% overall clinical benefit rate. Five patients progressed. One of the responding patients had previously failed to respond to both sorafenib and sunitinib. The results are as follows:

50 1200

or or

100 mg 900 mg

Protocol 207
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 4, 2012 /PRNewswire-iReach/ -- MediGain, a ... analytics, today announced the release of OptimOncology, a ... financial costing for office-based oncology practices.  This unique ... and provides measurable results for oncology practices. ...
... 2012 /PRNewswire-iReach/ -- Semantelli Corporation announced ... chosen Semantelli,s CoProtect® to manage its online ... life sciences industries, first compliance ready, actionable ... http://photos.prnewswire.com/prnh/20120104/CG30171 ) Semantelli,s compliance ready, ...
Cached Medicine Technology:MediGain Announces Release of New Oncology Analytics Solution 2Global Pharma Selects Semantelli's Compliance Ready Social Listening Platform to Manage Corporate Reputation 2
(Date:4/23/2014)... tract has long been considered to be between 180 ... have used refined microscopic techniques that indicate a much ... gastro-intestinal tract is only as large as a normal ... tract, which passes from the mouth through the esophagus ... about 5 meters in a normal adult, and is ...
(Date:4/23/2014)... doctors predict which patients might suffer potentially fatal side-effects ... which assesses brain scans using pattern recognition software similar ... has been developed by researchers at Imperial College London. ... Trust, which used the software are published in the ... over 15 million people each year worldwide. Ischemic strokes ...
(Date:4/23/2014)... American Gastroenterological Association (AGA) Research Foundation is pleased ... AGA Research Scholar Awards program, launched in 1984, ... research careers in digestive diseases. This year, the ... allowing for three consecutive years of funding. , ... are paving the way for promising research developments ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... 21, 2014 Five for-profit and non-profit organizations ... million in Proof of Concept grants to accelerate ... commercial products, the Life Sciences Discovery Fund (LSDF) ... Mentoring Program grant to the Washington Biotechnology & ... network to train the next generation of entrepreneurs ...
Breaking Medicine News(10 mins):Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2
... (Nasdaq: ONXX ) today announced that it ... Conference on Thursday,May 1, at 8:00 a.m. Eastern ... of the presentation on our website at:, ... listeners log on 15 minutes early in order ...
... Mich., April 24 The Perrigo Company,(Nasdaq: PRGO ... from the,U.S. Food and Drug Administration (FDA) to market ... 4 mg (base) (Orange, Coated)., The FDA has ... drug, GlaxoSmithKline,s Nicorette(R) Gum, 2 mg (base) and 4 ...
... Courage Center is hosting a,credentialed educational forum on ... Golden Valley Road. The session offers three CEUs, ... Worker." Registration is from,8-8:30am with the session itself ... Golden Valley., Session participants will gain a ...
... LOUISVILLE, Ky., April 24 Ventas, Inc. (NYSE:,VTR) ... its May,19, 2008 annual meeting of shareholders, the Company,s ... $10 billion NYSE-listed real estate investment trust with assets,in ... Chicago as our,headquarters will provide the Company with increased ...
... difference after 65, study finds , , THURSDAY, April 24 (HealthDay News) ... money, appears to apply to the risk of stroke, a new ... stroke between the ages of 50 and 64, according to the ... Michigan Health and Retirement Study. , And the most probable reason ...
... WEST CHESTER, Ohio, April 24 Employees at ... a voluntary program,designed to promote healthy lifestyles. Modeled after ... salaried employees began a,12-week weight-loss contest in January -- ... a combined 4,256 pounds -- more than two tons ...
Cached Medicine News:Health News:Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum 2Health News:Ventas Names Chicago as Headquarters 2Health News:Ventas Names Chicago as Headquarters 3Health News:Ventas Names Chicago as Headquarters 4Health News:Ventas Names Chicago as Headquarters 5Health News:Higher Wealth Linked to Lower Risk of Early Stroke 2Health News:Higher Wealth Linked to Lower Risk of Early Stroke 3Health News:AK Steel Employees Compete for the Health of It 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: